SERONO OFFERS MULTIPLE SCLEROSIS TREATMENT
By Adnews Staff
Serono Canada recently launched a new drug that delays the progression of relapsing remitting multiple sclerosis. Called Rebif, the drug is available in a ready-to-use, pre-filled, liquid syringe that can be injected subcutaneously. It comes in two dosages: 22 mcg and 44 mcg, and is administered three-times-a-week. Serono says Rebif delays progression to disability, reduces the number and severity of relapses and reduces disease activity. Rebif will be promoted using print ads in medical journals and PR. The print ads will be created by Medicus Intercon of Toronto. Thornley Fallis of Toronto will handle PR. MS is a chronic, progressive disease of the central nervous system. It is associated with periods of disability alternating with periods of recovery. Symptoms include impaired vision, spasticity, tingling and paralysis.